> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lilly Gains Approval for Alimta/Keytruda/Carboplatin Combo
- URL: https://www.fdaweb.com/lilly-gains-approval-for-alimta-keytruda-carboplatin-combo/
- Published: 2018-06-05T12:00:00.000Z
- Updated: 2026-09-15T00:10:30.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141605

FDA has approved Eli Lilly’s Alimta (pemetrexed for injection) in combination with carboplatin and Merck’s Keytruda (pembrolizumab) for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer, irrespective of PD-L1 expression status. Previously, the combination use was permitted under an accelerated approval. The full approval is based on data from Merck’s KEYNOTE-021 study, Cohort G1\. Data showed that the triple combination provided a statistically significant improvement in objective response rate versus Alimta plus carboplatin alone, Lilly says.